Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab versus placebo for moderate-to-severe genital psoriasis
NL-OMON53160Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in genital psoriasis comparing Ixekizumab Q2W during blinded period with Placebo Q2W during blinded period (2 arms). Started Jul 2016; status: recruiting.
02
Drugs
ixekizumab
03
Conditions
genital psoriasis
Beyond the preview
Go deeper on NL-OMON53160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53160.